CN104328178A - Primer pair for simultaneously detecting E2A-PBX1, TEL-AML1 and MLL-AF4 fusion genes by pyrosequencing process and kit including primer pair - Google Patents
Primer pair for simultaneously detecting E2A-PBX1, TEL-AML1 and MLL-AF4 fusion genes by pyrosequencing process and kit including primer pair Download PDFInfo
- Publication number
- CN104328178A CN104328178A CN201410589115.9A CN201410589115A CN104328178A CN 104328178 A CN104328178 A CN 104328178A CN 201410589115 A CN201410589115 A CN 201410589115A CN 104328178 A CN104328178 A CN 104328178A
- Authority
- CN
- China
- Prior art keywords
- mll
- primer
- tel
- pbx1
- aml1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a primer pair for simultaneously detecting E2A-PBX1, TEL-AML1 and MLL-AF4 fusion genes by a pyrosequencing process and a kit including the primer pair. The kit can be used for detecting a plurality of fusion genes E2A-PBX1, TEL-AML1, MLL-AF4(e9/e5), MLL-AF4(e9/e4) and MLL-AF4(e10/e4) at a time. By designing primers for mRNA of the E2A-PBX1, TEL-AML1 and MLL-AF4 fusion genes and performing sequencing analysis on products after performing reverse transcription PCR, the kit disclosed by the invention can be used for realizing quick, accurate and high-flux detection on the E2A-PBX1, TEL-AML1 and MLL-AF4 fusion genes.
Description
Technical field
The invention belongs to biology field, be specifically related to the primer pair that a kind of Manganic pyrophosphate complex initiation method detects E2A-PBX1, TEL-AML1 and MLL-AF4 fusion gene simultaneously, comprise the test kit of described primer pair and the application of this test kit.
Background technology
E2A-PBX1, TEL-AML1, MLL-AF4 (e9/e5), MLL-AF4 (e9/e4), MLL-AF4 (e10/e4) fusion gene are fusion genes common in acute lymphoblastic leukemia (ALL).
In the method for the outer widely used molecular Biological Detection E2A-PBX1 of Present Domestic, TEL-AML1, MLL-AF4 fusion gene, fluorescence in situ hybridization technique (FISH) can only carry out qualitative detection, complicated operation; Quantitative fluorescent PCR also exists the limitation detecting flux, so all really can't meet the needs of clinical diagnosis detection.Traditional solid phase biological chip (Biochip) or biochip technology also exist repeatable poor, insufficient sensitivity good and the outstanding weakness of complex operation.
Pyrosequencing techniques (Pyrosequencing) is DNA sequence analysis technology of new generation, possess the ability of simultaneously a large amount of sample being carried out to sequencing analysis, for high-throughput, low cost, carry out nucleotide analysis and Clinical Laboratory provides ideal technological operation platform quickly and intuitively.
Summary of the invention
Goal of the invention: for the technical problem existed in prior art, the present invention proposes the test kit that a kind of Manganic pyrophosphate complex initiation method detects E2A-PBX1, TEL-AML1 and MLL-AF4 fusion gene simultaneously, has the advantages such as highly sensitive, high specific, split hair caccuracy, detection be rapid.
Technical scheme: for realizing above-mentioned technical purpose, the present invention proposes the primer pair of a kind of Manganic pyrophosphate complex initiation method detection E2A-PBX1, TEL-AML1, MLL-AF4 (e9/e5), MLL-AF4 (e9/e4) and MLL-AF4 (e10/e4) fusion gene, it is characterized in that, described primer pair comprises:
(1) for E2A-PBX1 gene,
Amplimer is:
Upstream primer: 5 '-GGCCTCCCGACTCCTACA-3 ',
Downstream primer: 5 '-CTGGGGGTCTGTGGGTTC-3 ',
Wherein 5 ' end of downstream primer carries out biotin labeling;
Sequencing primer is:
5′-GCTCCTCGGATACTCAA-3′；
(2) for TEL-AML1 gene:
Amplimer is:
Upstream primer: 5 '-CCATGCCCATTGGGAGAATAG-3 ',
Downstream primer: 5 '-TCGTGGACGTCTCTAGAAGGATTC-3 ',
Wherein 5 ' end of downstream primer carries out biotin labeling;
Sequencing primer:
5′-GATTCATTCCAAGTATGC-3′
(3) for MLL-AF4 (e9/e5) and MLL-AF4 (e9/e4) gene:
Amplimer is:
Upstream primer: 5 '-CCGCCCAAGTATCCCTGTAAAAC-3 ',
Downstream primer: 5 '-AAAGGAGGCGGCCATGAA-3 ',
Wherein 5 ' end of downstream primer carries out biotin labeling;
Sequencing primer:
5′-AAAACAAAAACCAAAAGA-3′
(4) for MLL-AF4 (e10/e4) gene:
Amplimer is:
Upstream primer: 5 '-TCTCCAATGGCAATAGTTCTAAGC-3 ',
Downstream primer: 5 '-GCTCAGCTGTACTAGGCGTATGT-3 ',
Wherein 5 ' end of downstream primer carries out biotin labeling;
Sequencing primer:
5′-TGGACTTCATTGGAGTAG-3′
Present invention further proposes the test kit that a kind of Manganic pyrophosphate complex initiation method detects E2A-PBX1, TEL-AML1, MLL-AF4 (e9/e5), MLL-AF4 (e9/e4) and MLL-AF4 (e10/e4) fusion gene simultaneously, described fusion gene is any one or a few in E2A-PBX1, TEL-AML1, MLL-AF4 (e9/e5), MLL-AF4 (e9/e4), MLL-AF4 (e10/e4), it is characterized in that, described test kit comprises following primer:
(1) for E2A-PBX1 gene,
Amplimer is:
Upstream primer: 5 '-GGCCTCCCGACTCCTACA-3 ',
Downstream primer: 5 '-CTGGGGGTCTGTGGGTTC-3 ',
Wherein 5 ' end of downstream primer carries out biotin labeling;
Sequencing primer is:
5′-GCTCCTCGGATACTCAA-3′；
(2) for TEL-AML1 gene:
Amplimer is:
Upstream primer: 5 '-CCATGCCCATTGGGAGAATAG-3 ',
Downstream primer: 5 '-TCGTGGACGTCTCTAGAAGGATTC-3 ',
Wherein 5 ' end of downstream primer carries out biotin labeling;
Sequencing primer:
5′-GATTCATTCCAAGTATGC-3′；
(3) for MLL-AF4 (e9/e5) and MLL-AF4 (e9/e4) gene:
Amplimer is:
Upstream primer: 5 '-CCGCCCAAGTATCCCTGTAAAAC-3 ',
Downstream primer:
5′-AAAGGAGGCGGCCATGAA-3′，
Wherein 5 ' end of downstream primer carries out biotin labeling;
Sequencing primer:
5′-AAAACAAAAACCAAAAGA-3′；
(4) for MLL-AF4 (e10/e4) gene:
Amplimer is:
Upstream primer: 5 '-TCTCCAATGGCAATAGTTCTAAGC-3 ',
Downstream primer: 5 '-GCTCAGCTGTACTAGGCGTATGT-3 ',
Wherein 5 ' end of downstream primer carries out biotin labeling;
Sequencing primer:
5′-TGGACTTCATTGGAGTAG-3′。
Described test kit also comprises quality control product.Described quality control product comprises positive reference substance and negative controls, wherein, described positive reference substance is the mixed solution of the plasmid containing E2A-PBX1, TEL-AML1, MLL-AF4 (e9/e5), MLL-AF4 (e9/e4) and MLL-AF4 (e10/e4), described negative controls is as positive reference substance reference, compared with described positive control, for not containing the plasmid solution of E2A-PBX1, TEL-AML1, MLL-AF4 (e9/e5), MLL-AF4 (e9/e4) and MLL-AF4 (e10/e4).
The test kit that the invention allows for above-mentioned primer pair and comprise above-mentioned primer pair detects the application in the reagent of E2A-PBX1, TEL-AML1 and MLL-AF4 fusion gene in preparation.
Beneficial effect: compared with prior art, Manganic pyrophosphate complex initiation method of the present invention detects E2A-PBX1 simultaneously, the test kit of TEL-AML1 and MLL-AF4 fusion gene can realize fast, easy, efficiently, detect E2A-PBX1 accurately, TEL-AML 1, MLL-AF4 (e9/e5), MLL-AF4 (e9/e4) and MLL-AF4 (e10/e4) fusion gene, for for the preparation of detecting E2A-PBX1 simultaneously, TEL-AML1, MLL-AF4 (e9/e5), the reagent of MLL-AF4 (e9/e4) and MLL-AF4 (e10/e4) fusion gene provides theoretical basis.
Embodiment
Experiment material:
Primer is synthesized by invitrogen company; Trizol is purchased from invitrogen company; Reverse transcription cDNA synthetic agent box is purchased in Fermentas company; Multiple PCR reagent kit is purchased in QIAGEN company; Manganic pyrophosphate complex initiation reagent is purchased in QIAGEN company.
Manganic pyrophosphate complex initiation method detects a test kit for E2A-PBX1, TEL-AML1, MLL-AF4 fusion gene, comprises quality control product and following primer:
(1) for E2A-PBX1 gene,
Amplimer is:
Upstream primer: 5 '-GGCCTCCCGACTCCTACA-3 ',
Downstream primer: 5 '-CTGGGGGTCTGTGGGTTC-3 ',
Wherein 5 ' end of downstream primer carries out biotin labeling;
Sequencing primer is:
5′-GCTCCTCGGATACTCAA-3′；
(2) for TEL-AML1 gene:
Amplimer is:
Upstream primer: 5 '-CCATGCCCATTGGGAGAATAG-3 ',
Downstream primer: 5 '-TCGTGGACGTCTCTAGAAGGATTC-3 ',
Wherein 5 ' end of downstream primer carries out biotin labeling;
Sequencing primer:
5′-GATTCATTCCAAGTATGC-3′
(3) for MLL-AF4 (e9/e5) and MLL-AF4 (e9/e4) gene:
Amplimer is:
Upstream primer: 5 '-CCGCCCAAGTATCCCTGTAAAAC-3 ',
Downstream primer:
5′-AAAGGAGGCGGCCATGAA-3′，
Wherein 5 ' end of downstream primer carries out biotin labeling;
Sequencing primer:
5′-AAAACAAAAACCAAAAGA-3′
(4) for MLL-AF4 (e10/e4) gene:
Amplimer is:
Upstream primer: 5 '-TCTCCAATGGCAATAGTTCTAAGC-3 ',
Downstream primer: 5 '-GCTCAGCTGTACTAGGCGTATGT-3 ',
Wherein 5 ' end of downstream primer carries out biotin labeling;
Sequencing primer:
5′-TGGACTTCATTGGAGTAG-3′
Wherein, quality control product (quality control product DNA) comprises positive reference substance and negative controls, positive reference substance is the mixed solution of the plasmid containing E2A-PBX1, TEL-AML1, MLL-AF4 (e9/e5), MLL-AF4 (e9/e4), MLL-AF4 (e10/e4), described negative controls as the contrast of positive reference substance, for not containing E2A-PBX1, TEL-AML1, MLL-AF4 (e9/e5), MLL-AF4 (e9/e4), MLL-AF4 (e10/e4) plasmid solution.
Detection method comprises the steps:
(1) RNA extracts:
Get the clinical sample of 16 acute lymphoblastic leukemia (ALL) patients; The clinical sample of 1 ~ No. 16 patient extracts RNA respectively according to the following steps:
(1) lymphocyte extract: get fresh whole blood 2ml and add 1ml 3wt% Trisodium Citrate, after mixing at 4 DEG C the centrifugal 10min of 3000r/min, get pale yellow chromatograph on blood cell layer and be lymphocyte, obtain lymphocyte liquid;
(2) get 1 centrifuge tube (through DEPC water treatment), add the lymphocyte liquid 150 μ l in (1), then add 1ml Trizol, room temperature places 5min, makes its abundant cracking;
The centrifugal 5min of (3) 12,000r/min, gets supernatant;
(4) in supernatant, add 200 μ l chloroforms, after acute vibration mixing, room temperature places 15min;
Centrifugal 15min under (5) 4 DEG C 12,000g;
(6) draw upper strata aqueous phase, aqueous phase is transferred in another centrifuge tube;
(7) in aqueous phase, add 500 μ l Virahol mixings, room temperature places 5 ~ 10min;
Centrifugal 10min under (8) 4 DEG C 12,000g, abandons supernatant, and RNA is sunken at the bottom of pipe;
(9) in the pipe of step (8), add 1ml 75% (v/v) ethanol, gentle vibration centrifuge tube, suspend precipitation;
(10) 4 DEG C of 8,000g centrifugal 5min, abandons supernatant as far as possible;
(11) room temperature is dried or vacuum-drying 5 ~ 10min;
(12) with 50ul RNase-free dH
2o dissolves RNA sample, 55 ~ 60 DEG C, 5 ~ 10min;
(13) the quantitative RNA concentration of OD value is surveyed.
According to above-mentioned steps, obtain the mRNA of 1 ~ No. 16 sample respectively.
(2) multiple reverse transcription pcr amplification:
Respectively multiple reverse transcription pcr amplification is carried out to the mRNA of above-mentioned 1 ~ No. 16 sample as follows:
(1) synthesis of cDNA first chain
1. get the centrifuge tube of a RNase-free, be placed on ice, set up following reaction system;
Total RNA 5～10μg/3μl
Oligo(dT)18Primer(0.5μg/μl) 1μl
RNase-free dH
2o adds to 12 μ l
Mix reaction solution gently, with the reaction solution on the centrifugal a little collection tube wall of refrigerated centrifuge at the bottom of pipe;
2. centrifuge tube was in 70 DEG C of incubations 5 minutes, took out rapidly to be afterwards placed in ice and to cool, with the reaction solution on the centrifugal a little collection tube wall of refrigerated centrifuge at the bottom of pipe;
3. centrifuge tube is positioned on ice, is sequentially added into following reaction solution;
5×reaction buffer 4μl
RNase Inhibitor(20U/μl) 1μl
10mM dNTPs Mix 2μl
Mix reaction solution gently, with the reaction solution on the centrifugal a little collection tube wall of refrigerated centrifuge at the bottom of pipe;
4. centrifuge tube was in 37 DEG C of incubations 5 minutes;
5. add 1 μ l RevertAidTM Reverse Transcriptase (200U/ μ l), final volume is 20 μ l;
6. centrifuge tube was in 42 DEG C of reactions 60 minutes;
7. centrifuge tube is in 70 DEG C of heating, 10 minutes termination reactions, and rapid taking-up is afterwards placed in ice and cools.
So, synthesis cDNA first chain, i.e. template cDNA (Template cDNA).
(2) multiplex PCR
What adopt is the Multiplex PCR kit of QIAGEN company, and system is as follows
Wherein, warm start TaqDNA enzyme, MgCl2 and dNTP Mix is contained in 2 × QIAGEN Multiplex PCR Master Mix; 10 × Primer mix is the mixture comprising above-mentioned three kinds of fusion gene primer pairs.
Pcr amplification program: 95 DEG C of 15min; 94 DEG C of 30s, 55 DEG C of 90s, 72 DEG C of 90s, 35 circulations; 72 DEG C of 10min; 4 DEG C of insulations.
By above-mentioned steps, obtain PCR primer.
(3) Manganic pyrophosphate complex initiation
First, fix PCR primer with microballon, biotin labeled PCR primer is mainly fixed on the Agarose microbead (Streptavidin Sepharose High Performance) of Streptavidin bag quilt by it, comprises the steps:
(1) jog bag is by the Agarose microbead of Streptavidin, until obtain homogeneous solution;
(2) in a test tube, mix the Agarose microbead total amount (2 μ l/ sample) of Streptavidin bag quilt and binding buffer liquid (40 μ l/ sample), add ultrapure water to certain volume, this volume and the follow-up summation will adding the volume of the biotin labeled PCR primer optimized are 80 μ l/ holes;
(3) solution of the certain volume obtained in (2) is added in 24 hole PCR orifice plates;
(4) arrange according to orifice plate, the biotin labeled PCR primer that interpolation 5 ~ 20 μ l have optimized, to each hole slot of PCR orifice plate, makes wherein solution contained by every hole be 80 μ l;
(5) use orifice plate bar lid sealing PCR orifice plate, guarantee not leak between hole slot;
(6) shaker mixer (1400rpm) continuous vibration PCR orifice plate at least 5 ~ 10 minutes are used.
Through above-mentioned steps, biotin labeled PCR primer is fixed on the Agarose microbead of Streptavidin bag quilt.
Then, start vacuum work station preparation work, comprise the steps:
(1) following reagent is prepared: approximately 50ml 70% (v/v) ethanol; About 40ml denaturing soln (QIAGEN company); About 50ml 1 × lavation buffer solution (QIAGEN company)); About 50ml ultrapure water; About 70ml ultrapure water;
(2) open vacuum pump: open vacuum switch, carry out testing experiment, to determine whether filter probe normally works;
(3) permeability of filter probe is detected before each use vacuum pump with ultrapure water, centrifuge tube previously prepd being installed ultrapure water is inserted in PCR device, filter probe is fallen in ultrapure water, ultrapure water, as being evacuated in 20 seconds, shows that filter probe is normal, can use, otherwise then need to change filter probe;
(4) take off the PCR orifice plate vibrated, sample is put into PCR device, carefully fall filter probe in PCR orifice plate, stop 15 seconds; Guarantee that solution is all sucked away, to catch the microballon containing fixed die plate;
(5) vacuum unit is moved to the first reagent trough containing 70% (v/v) ethanol, washing and filtering probe 5 seconds;
(6) vacuum unit is moved to the second reagent trough containing denaturing soln, washing and filtering probe 5 seconds;
(7) vacuum unit is moved to the 3rd reagent trough containing lavation buffer solution, washing and filtering probe 10 seconds;
(8) vacuum unit is raised more than 90 ° of vertical lines 5 seconds, discharge opeing from filter probe;
(9) grip vacuum unit on Q24 orifice plate, the vacuum switch on stopping device unsettled stop 5 seconds, allow negative pressure leave;
(10) by left and right jog vacuum unit, release pearl is in the orifice plate containing 3 kinds of sequencing primers;
(11) when vacuum unit cuts out, vacuum unit is transferred to the 4th reagent trough containing ultrapure water, vibrates 10 seconds;
(12) fall probe to another containing ultrapure water the 5th reagent trough in and apply vacuum, cleaning probe, with 70ml ultrapure water filter probe;
(13) vacuum unit is raised more than 90 ° of vertical lines 5 seconds, discharge opeing from filter probe;
(14) close the switch on vacuum unit, and be placed on static (P) position.
Change like this completes the preparation work of vacuum station, then starts DNA isolation strand and is discharged into by sample in PyroMark Q24 orifice plate, comprising the steps: particularly
(1) 80 DEG C of exact heat 2 minutes on orifice plate base PyroMark Q24 orifice plate being placed on preheating;
(2) take off orifice plate from orifice plate base, make sample at room temperature at least cool 5 minutes.
Through above-mentioned steps, sample is discharged in PyroMark Q24 orifice plate by cup.Then prepare PyroMarkQ24 reagent, carry out in the steps below:
(1) open PyroMark Q24 test kit and take out the bottle containing enzyme and substrate lyophilized powder, and the test tube containing Nucleotide;
(2) dissolve and packing enzyme and substrate according to test kit specification sheets ultrapure water, all reagent re-uses after need recovering room temperature;
(3) according to the volume that computer calculation goes out, in agent bin, enzyme, substrate and Nucleotide A, T, G, C (agent bin uses at most 30 times, and agent bin must be dry before use) is added.
After getting out PyroMark Q24 reagent, PyroMark Q24 instrument is tested in the steps below:
(1) PyroMark Q24 software is opened, click new assay (newly testing) → new AQ assay (new AQ test) → input catastrophe point sequence in sequence to analyze (sequence to be analyzed), click Generate Dispensation Order (generation allocation order), click and preserve;
(2) click new run (newly running) → Instrument method (instrumental method) → 007, then click the grid that will check order, click and be saved to USB flash disk;
(3) by the USB port before the USB flash disk inserting instrument containing operating file;
(4) orifice plate heated is put on instrument;
(5) label surface of agent bin (enzyme, substrate and Nucleotide) is put into instrument towards oneself, orifice plate put into by open holes board support frame, closes orifice plate support saddle frame and instrument lid;
(6) select Run (operation), and press OK;
(7) after entering Run (operation), the file that will run is selected by select (selection);
(8) instrument end of run after confirming that operating file is saved to USB flash disk, by close, takes out USB flash disk;
(9) open instrument, take out agent bin, and it is cleaned repeatedly, discarded orifice plate;
(10) when instrument does not run, select shutdown (shutdown) from master menu and press OK;
(11) when It is now safe to turn offthe instrument (now can safety shutdown) occurs, can close instrument, power switch is positioned at after instrument.
(4) interpretation of result:
Open Pyromark Q24 software, analyze the type of E2A-PBX1, TEL-AML1, MLL-AF4 (e9/e5, e9/e4), MLL-AF4 (e10/e4) fusion gene, analytical results is as following table:
Result shows, 3,7,10,13, No. 15 patients are that E2A-PBX1 fusion gene is positive; 1,5,8, No. 12 patients are that TEL-AML1 fusion gene is positive; 4,9,14, No. 16 patients are that MLL-AF4 (e10/e4) fusion gene is positive; 2,6, No. 11 patients are that MLL-AF4 (e9/e5) and MLL-AF4 (e9/e4) fusion gene are positive.
To sum up, apply test kit of the present invention can realize quick, easy, detect E2A-PBX1, TEL-AML1, MLL-AF4 (e9/e5), MLL-AF4 (e9/e4) and MLL-AF4 (e10/e4) fusion gene efficiently, accurately.
About after those set forth of the present invention more than having read, those skilled in the art can do various amendment or change to the present invention, comprising the various changes of primer, these equivalent form of values belong to the scope defined in the application's appended claims equally.
Claims (6)
1. a Manganic pyrophosphate complex initiation method detects the primer pair of E2A-PBX1, TEL-AML1 and MLL-AF4 fusion gene simultaneously, wherein, described MLL-AF4 fusion gene comprise in MLL-AF4 (e9/e5), MLL-AF4 (e9/e4) and MLL-AF4 (e10/e4) any one or a few, it is characterized in that, described primer pair comprises:
(1) for E2A-PBX1 gene,
Amplimer is:
Upstream primer: 5 '-GGCCTCCCGACTCCTACA-3 ',
Downstream primer: 5 '-CTGGGGGTCTGTGGGTTC-3 ',
Wherein 5 ' end of downstream primer carries out biotin labeling;
Sequencing primer is:
5′-GCTCCTCGGATACTCAA-3′；
(2) for TEL-AML1 gene:
Amplimer is:
Upstream primer: 5 '-CCATGCCCATTGGGAGAATAG-3 ',
Downstream primer: 5 '-TCGTGGACGTCTCTAGAAGGATTC-3 ',
Wherein 5 ' end of downstream primer carries out biotin labeling;
Sequencing primer:
5′-GATTCATTCCAAGTATGC-3′
(3) for MLL-AF4 (e9/e5) and MLL-AF4 (e9/e4) gene:
Amplimer is:
Upstream primer: 5 '-CCGCCCAAGTATCCCTGTAAAAC-3 ',
Downstream primer:
5′-AGCGGCTTCACTCAGACCCTAAAGGAGGCGGCCATGAA-3′，
Wherein 5 ' end of downstream primer carries out biotin labeling;
Sequencing primer:
5′-AAAACAAAAACCAAAAGA-3′
(4) for MLL-AF4 (e10/e4) gene:
Amplimer is:
Upstream primer: 5 '-TCTCCAATGGCAATAGTTCTAAGC-3 ',
Downstream primer: 5 '-GCTCAGCTGTACTAGGCGTATGT-3 ',
Wherein 5 ' end of downstream primer carries out biotin labeling;
Sequencing primer:
5′-TGGACTTCATTGGAGTAG-3′。
2. a Manganic pyrophosphate complex initiation method detects the test kit of E2A-PBX1, TEL-AML1 and MLL-AF4 fusion gene simultaneously, described MLL-AF4 fusion gene comprises any one or two kinds in MLL-AF4 (e9/e5), MLL-AF4 (e9/e4) and MLL-AF4 (e10/e4), it is characterized in that, described test kit comprises following primer:
(1) for E2A-PBX1 gene,
Amplimer is:
Upstream primer: 5 '-GGCCTCCCGACTCCTACA-3 ',
Downstream primer: 5 '-CTGGGGGTCTGTGGGTTC-3 ',
Wherein 5 ' end of downstream primer carries out biotin labeling;
Sequencing primer is:
5′-GCTCCTCGGATACTCAA-3′；
(2) for TEL-AML1 gene:
Amplimer is:
Upstream primer: 5 '-CCATGCCCATTGGGAGAATAG-3 ',
Downstream primer: 5 '-TCGTGGACGTCTCTAGAAGGATTC-3 ',
Wherein 5 ' end of downstream primer carries out biotin labeling;
Sequencing primer:
5′-GATTCATTCCAAGTATGC-3′
(3) for MLL-AF4 (e9/e5) and MLL-AF4 (e9/e4) gene:
Amplimer is:
Upstream primer: 5 '-CCGCCCAAGTATCCCTGTAAAAC-3 ',
Downstream primer:
5′-AAAGGAGGCGGCCATGAA-3′，
Wherein 5 ' end of downstream primer carries out biotin labeling;
Sequencing primer:
5′-AAAACAAAAACCAAAAGA-3′
(4) for MLL-AF4 (e10/e4) gene:
Amplimer is:
Upstream primer: 5 '-TCTCCAATGGCAATAGTTCTAAGC-3 ',
Downstream primer: 5 '-GCTCAGCTGTACTAGGCGTATGT-3 ',
Wherein 5 ' end of downstream primer carries out biotin labeling;
Sequencing primer:
5′-TGGACTTCATTGGAGTAG-3′。
3. test kit according to claim 2, is characterized in that, described test kit comprises quality control product, and described quality control product comprises positive reference substance and negative controls.
4. test kit according to claim 3, it is characterized in that, described positive reference substance is the mixed solution of the plasmid containing E2A-PBX1, TEL-AML1, MLL-AF4 (e9/e5), MLL-AF4 (e9/e4) and MLL-AF4 (e10/e4), and described negative controls is not containing the plasmid solution of E2A-PBX1, TEL-AML1, MLL-AF4 (e9/e5), MLL-AF4 (e9/e4) and MLL-AF4 (e10/e4).
5. the application of primer pair according to claim 1 on the reagent for the preparation of detection E2A-PBX1, TEL-AML1 and MLL-AF4 fusion gene.
6. claim 2 or the application of test kit according to claim 3 on the reagent for the preparation of detection E2A-PBX1, TEL-AML1 and MLL-AF4 fusion gene.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410589115.9A CN104328178A (en) | 2014-09-23 | 2014-10-28 | Primer pair for simultaneously detecting E2A-PBX1, TEL-AML1 and MLL-AF4 fusion genes by pyrosequencing process and kit including primer pair |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410490713 | 2014-09-23 | ||
| CN201410490713.0 | 2014-09-23 | ||
| CN201410589115.9A CN104328178A (en) | 2014-09-23 | 2014-10-28 | Primer pair for simultaneously detecting E2A-PBX1, TEL-AML1 and MLL-AF4 fusion genes by pyrosequencing process and kit including primer pair |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104328178A true CN104328178A (en) | 2015-02-04 |
Family
ID=52402982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410589115.9A Pending CN104328178A (en) | 2014-09-23 | 2014-10-28 | Primer pair for simultaneously detecting E2A-PBX1, TEL-AML1 and MLL-AF4 fusion genes by pyrosequencing process and kit including primer pair |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104328178A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107345244A (en) * | 2016-10-12 | 2017-11-14 | 深圳市儿童医院 | Detect method, primer and the kit of leukaemia TEL AML1 fusions |
| CN111500689A (en) * | 2020-05-06 | 2020-08-07 | 南京实践医学检验有限公司 | Method for detecting M LL-AF 4 fusion gene |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102634572A (en) * | 2012-01-16 | 2012-08-15 | 中山大学达安基因股份有限公司 | Reagent kit for detecting mRNA (messenger ribonucleic acid) expression of fused gene E2A-PBX1 via fluorescent quantitative RT-PCR (reverse transcription-polymerase chain reaction) |
-
2014
- 2014-10-28 CN CN201410589115.9A patent/CN104328178A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102634572A (en) * | 2012-01-16 | 2012-08-15 | 中山大学达安基因股份有限公司 | Reagent kit for detecting mRNA (messenger ribonucleic acid) expression of fused gene E2A-PBX1 via fluorescent quantitative RT-PCR (reverse transcription-polymerase chain reaction) |
Non-Patent Citations (5)
| Title |
|---|
| ALBITAR, M.: "《Leukemias: Principles and Practice of Therapy》", 1 January 2011 * |
| SUDHAKAR N. ET AL.: "RT-PCR and real-time PCR analysis of E2A-PBX1,TEL-AML1, mBCR-ABL and MLL-AF4 fusion gene transcripts in de novo B-lineage acute lymphoblastic leukaemia patients in south India", 《J.GENET》 * |
| SUDHAKAR N. ET AL.: "RT-PCR and real-time PCR analysis ofE2A-PBX1,TEL-AML1, mBCR-ABLandMLL-AF4fusion gene transcripts inde novoB-lineage acute lymphoblastic leukaemia patients in south India", 《J. GENET》 * |
| 府伟灵等: "临床分子生物学检验", 《临床分子生物学检验》 * |
| 王艳茹等: "应用焦磷酸测序法检测MEG3基因在急性髓系白血病中的甲基化状态", 《广东医学》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107345244A (en) * | 2016-10-12 | 2017-11-14 | 深圳市儿童医院 | Detect method, primer and the kit of leukaemia TEL AML1 fusions |
| CN111500689A (en) * | 2020-05-06 | 2020-08-07 | 南京实践医学检验有限公司 | Method for detecting M LL-AF 4 fusion gene |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Absolute quantification of lung cancer related microRNA by droplet digital PCR | |
| Galletti et al. | Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential | |
| Marsavela et al. | Melanoma circulating tumor cells: Benefits and challenges required for clinical application | |
| CA3038262A1 (en) | Fluidic system and related methods | |
| US8304188B2 (en) | Barriers for facilitating biological reactions | |
| Reinholz et al. | Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437 | |
| Yu et al. | Multiple authentications of high-value milk by centrifugal microfluidic chip-based real-time fluorescent LAMP | |
| EP2307028A1 (en) | Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy | |
| US11123740B2 (en) | Systems and methods for continuous flow digital droplet polymerase chain reaction bioanalysis | |
| CN104911251A (en) | Primer pair for detecting EML4-ALK fusion gene by pyrosequencing method and kit thereof | |
| JP2013521764A5 (en) | ||
| EP1774030A2 (en) | Identification of makers in esophageal cancer, colon cancer, head and neck cancer and melanoma | |
| Restaino et al. | Real-time multiplexed PCR using surface enhanced Raman spectroscopy in a thermoplastic chip | |
| JP2022516442A (en) | Methods and Compositions for Detecting Amplified Products | |
| Sun et al. | A bead-based microfluidic approach to integrated single-cell gene expression analysis by quantitative RT-PCR | |
| Yeo et al. | The usefulness of a novel fully automated PCR-based Idylla test for detection of the BRAF V600E mutation in thyroid tissue: comparison with PNA-clamping PCR, real-time PCR and pyrosequencing | |
| CN105087764A (en) | Detecting method for safely and quickly identifying porcine-derived materials in food and kit for detecting method | |
| CN114364811A (en) | Sample preparation apparatus with PCR chip and multi-well plate | |
| Hung et al. | An integrated microfluidic platform for rapid tumor cell isolation, counting and molecular diagnosis | |
| CN104328178A (en) | Primer pair for simultaneously detecting E2A-PBX1, TEL-AML1 and MLL-AF4 fusion genes by pyrosequencing process and kit including primer pair | |
| CN104313160A (en) | Primer pair for simultaneously detecting CBFB-MYH11 and AML1-ETO fusion genes with pyrosequencing method and kit | |
| CN104278092A (en) | Primer pair and kit for detecting PML-RARA fusion gene by use of pyrophosphoric acid sequencing method | |
| CN108823305A (en) | A kind of multiple PCR method of 8 kinds of tumour correlation long-chain non-coding RNAs of synchronous detection | |
| CN104357558A (en) | Primer pair for simultaneously detecting API2-MALT1 and NPM-ALK fusion genes by pyrosequencing process and kit | |
| CN104357557A (en) | Primer pair for detecting NPM1 (nucleophosmin) gene mutation by pyrosequencing process and kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150204 |
|
| RJ01 | Rejection of invention patent application after publication |